He earned his medical degree from Wayne State University School of Medicine, completed his residency at Case Western Reserve University (MetroHealth) and the Cleveland Clinic Foundation, and his fellowship at Yale University.
Dr. O’Malley is actively involved in improving the quality of patient care, safety and satisfaction. He serves as the chair of The James Committee on Patient Satisfaction and is a member of the Patient Experience Counsel, the Perioperative Quality Management Committee and The James Quality and Patient Safety Committee.
He is active nationally as a member of the Marketing and Communication Committee of the Society of Gynecologic Oncologists (SGO) and the Ovarian Cancer, Developmental Therapeutics and Membership Committees of the Gynecologic Oncology Group (GOG). Dr. O’Malley was appointed to the panel of the National Comprehensive Cancer Network (NCCN) Guidelines for Ovarian Cancer. Most recently, he accepted the invitation to be one of three U.S. members of the steering committee for TRINOVA 3, a multinational phase III ovarian cancer trial.
Dr. O’Malley’s drive to have no patient with a gynecologic cancer succumb to the disease guides his research that specializes in the development of therapeutics/treatments for gynecologic cancers, concentrating on ovarian and uterine (endometrial). He has designed, coordinated and published on phase I, II and III clinical trials with a special interest in compounds that effect angiogenesis. This led to him becoming the institutional principal investigator for the NCCN Ovarian Cancer Outcomes Project. Improving patient treatment options cannot be accomplished without understanding how the treatments are having an effect at the cellular level; therefore, Dr. O’Malley continues to participate in projects that help define these mechanisms. He continues to work to improve not only the therapies (chemotherapy) but to identify patients that would benefit (or not benefit) from adjuvant therapeutic options in ovarian and uterine cancer (specifically high risk histologies) patients.
Dr. O’Malley’s quest to improve patient outcomes has led him to working on improving surgical techniques. He has implemented robotic assisted minimally invasive surgical techniques in all aspects of practice, and published the improved outcomes of these techniques. Dr. O’Malley has collaborated across multiple medical specialties to identify ways to improve the technique and outcomes of how malignant cells are removed at the time of surgery (Ramen spectroscopy). Their team has submitted and been awarded grants to study these techniques. Dr. O’Malley’s research has been recognized with more than 50 publications.
These accomplishments resulted in Dr. O’Malley being named as one of the Best/Top Doctors in America by US News and World Report (Castle Connelly) and Best Doctors.
In his free time, Dr. O’Malley spends time with his wife and their four daughters.
- Named to the Castle Connolly list of America’s “Top Doctors” for 2015
- Rated in the top 10 percent of physicians in the nation for patient satisfaction, 2014, 2016
Wayne State University School of Medicine
Obstetrics / Gynecology
Case Western Reserve University
7/1/1999 - 6/30/2002
Specialties and conditions I treat
- Gynecologic Oncology
- Gynecologic Cancers
- Ovarian Cancers
- Uterine Cancers
- Minimally Invasive Surgical Procedures
- Endometrial Cancers
- Cervical Cancer
- Vaginal Cancers
- Vulvar Cancers
Locations where I practice
Stefanie Spielman Comprehensive Breast Center
More about my work
OB/GYN / Gynecological Oncology
Yale University School of Medicine
7/1/2002 - 6/30/2005
American Board of OB/GYN
American Board of OB/GYN (Subspecialty: Gynecologic Oncology)
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the University requires annual disclosures from all faculty members with external interests related to their University responsibilities.
As of 03/25/2016, Dr. O'Malley has reported no financial relationships with medical device, research and/or drug companies.